{"brief_title": "Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome", "brief_summary": "The main objective of this trial is to evaluate the efficacy and toxicity of intensive immuno-suppression with ATG + CSA versus best supportive care in patients with transfusion dependent low and intermediate risk myelodysplastic syndrome (MDS).", "detailed_description": "This trial will answer the question whether immuno-suppression improves hematopoesis and reduces transfusion requirements analogous to patients with aplastic anemia as the short-term outcome, and whether immuno-suppression accelerates leukemic transformation and influences survival as the long-term outcome. Primary endpoint: best response (CR + PR) rate at month 6", "condition": ["Myelodysplastic Syndromes"], "intervention_type": ["Drug", "Behavioral"], "intervention_name": ["ATG + CSA", "Supportive care"], "description": ["M\u00e9rieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)", "Patients randomized to this arm will be treated as outpatients."], "arm_group_label": ["Arm A: ATG + CSA", "Arm B: Supportive care"], "criteria": "Hypoplastic MDS, or MDS subtype RA, RAS or RAEB with \u2264 10% blasts, or RAEB with 10-20% blasts and the patient refusing or not eligible for the MDS high risk protocol (EORTC 06961) - Transfusion dependence < 24 months or neutrophils < 0.5 \u00d7 109/l. - ECOG/SAKK performance status \u2264 2 - Age > 18 years - No active uncontrolled infection - No prior chemotherapy or radiotherapy - No history of heart failure, clinically relevant cardiac arrhythmia or other hemato-oncological disease", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "secondary myelodysplastic syndromes", "mesh_term": ["Syndrome", "Myelodysplastic Syndromes", "Preleukemia", "Antilymphocyte Serum", "Cyclosporins", "Cyclosporine"], "id": "NCT00004208"}